EU nod for Libtayo plus chemo for advanced PD-L1 positive NSCLC

The European Commission (EC) has approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression, US biotech firm Regeneron (Nasdaq: REGN) revealed today.

This includes patients that have no EGFR, ALK or ROS1 aberrations and whose tumors are metastatic or locally advanced and not candidates for definitive chemoradiation, and marks the fifth approval for Libtayo in Europe.

“Today’s approval considerably expands the number of people in Europe with advanced non-small cell lung cancer who are eligible for Libtayo-based first-line treatment, including those with PD-L1 expression ranges most commonly seen in real-world practice,” said Dr Israel Lowy, senior vice president, translational and clinical sciences, oncology at Regeneron.